SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-094231
Filing Date
2024-08-09
Accepted
2024-08-08 17:51:38
Documents
57
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q nktr-20240630.htm   iXBRL 10-Q 2007158
2 EX-10.1(6) nktr-ex10_16.htm EX-10.1(6) 192161
3 EX-31.1 nktr-ex31_1.htm EX-31.1 13480
4 EX-31.2 nktr-ex31_2.htm EX-31.2 13690
5 EX-32.1 nktr-ex32_1.htm EX-32.1 9358
  Complete submission text file 0000950170-24-094231.txt   7943774

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nktr-20240630.xsd EX-101.SCH 1013340
59 EXTRACTED XBRL INSTANCE DOCUMENT nktr-20240630_htm.xml XML 1423813
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

IRS No.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-24006 | Film No.: 241189850
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)